Novavax (NVAX) Gross Profit (QoQ) (2011 - 2026)

Novavax (NVAX) Gross Profit (QoQ) (2011 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 65,538.84 Bn 65,538.56 Bn -
2 Nanobiotix 1,912.79 Bn 1,912.72 Bn -
3 Akari Therapeutics 1,009.43 Bn 1,009.43 Bn -
4 BeOne Medicines 469.46 Bn 464.67 Bn 1.35 Bn
5 Vertex Pharmaceuticals 122.69 Bn 115.45 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 70.41 Bn 61.65 Bn 3.31 Bn
7 Belite Bio 62.84 Bn 62.84 Bn -
8 Argenx Se 56.10 Bn 50.91 Bn 1.41 Bn
9 Alnylam Pharmaceuticals 37.48 Bn 34.47 Bn 959.66 Mn
10 Novavax 1.25 Bn 461.99 Mn 108.82 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -12.97%
Dec 31, 2025 155.44%
Sep 30, 2025 -69.34%
Jun 30, 2025 -75.53%
Mar 31, 2025 1,163.58%
Dec 31, 2024 116.14%
Sep 30, 2024 -93.53%
Jun 30, 2024 965.76%
Mar 31, 2024 -74.59%
Dec 31, 2023 54.86%
Sep 30, 2023 -76.11%
Jun 30, 2023 686.62%
Mar 31, 2023 -73.32%
Dec 31, 2022 -41.45%
Sep 30, 2022 452.29%
Jun 30, 2022 -112.36%
Mar 31, 2022 209.98%
Dec 31, 2021 24.24%
Sep 30, 2021 -39.99%
Jun 30, 2021 -33.36%